Corporate News

DryShips Inc. (Nasdaq: DRYS) entered into agreements to sell: The Panamax vessel MV Primera 72,495 dwt built in 1998 for US $75 million, The Panamax vessel MV Paragon 71,259 dwt built in 1995 for US $61 million, The Panamax vessel MV Menorca 71,662 dwt built in 1997 for US $77 million.

DryShips also entered into agreemetns to acquire: A 75,228 dwt Panamax vessel built in 2008 which is expected to be delivered within 2008; A 75,204 dwt Panamax vessel built in 2007 which is expected to be delivered within 2008, A 75,000 dwt Panamax vessel under construction in China scheduled to be delivered during the fourth quarter of 2008, A 75,000 dwt Panamax vessel under construction in China scheduled to be delivered during the first quarter of 2009.

In line with its strategy of selling older vessels and replacing them with modern vessels, the Company has entered into agreements to acquire the following vessels from companies beneficially owned by George Economou, Chairman and CEO of DryShips Inc., on terms that the Company believes are comparable to those that may be obtained from an independent third party.

CEO, George Economou, said, "The transactions reiterate our positive outlook on the fundamentals of the drybulk industry and reinforce our position of taking advantage of the strong freight environment with our large, versatile and modern fleet."

Deutsche Bank (NYSE: DB) announced that Bernardo Parnes will join the firm as of August as a Managing Director and Chief Country Officer for Deutsche Bank Brazil and a member of the Deutsche Bank Americas Executive Committee. Parnes will be based in Sao Paulo and report to Seth Waugh, CEO of Deutsche Bank Americas, and Dalinc Ariburnu, Global Head of Emerging Markets in Deutsche Bank's Global Markets division.

2K Games, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), announced that it has signed an agreement with Digital Extremes to assist in the development of BioShock(R) for the PLAYSTATION(R)3 computer entertainment system. Shipping to retailers in October 2008 with new features and content, the PLAYSTATION 3 system version of BioShock is being developed by 2K Marin, 2K Boston, 2K Australia and Digital Extremes.

Take-Two Interactive Software is a global developer, marketer, distributor and publisher of interactive entertainment software games

AK Steel (NYSE: AKS) has advised its customers that a $905 per ton surcharge will be added to invoices for electrical steel products shipped in August 2008. August 2008 surcharges for the broad range of stainless steel products that AK Steel produces can be found on the company's web site at www.aksteel.com.

AK Steel's surcharges are based on reported prices for raw materials and energy used to manufacture the products, with the June 2008 purchase cost used to determine the August 2008 surcharges.

AK Steel produces flat-rolled carbon, stainless and electrical steels, primarily for automotive, appliance, construction and electrical power generation and distribution markets

Regeneron Pharmaceuticals (Nasdaq: REGN) and Cellectis S.A. entered into an Amended and Restated Non-Exclusive License Agreement. The License Agreement resolves a dispute between the parties related to the interpretation of a license agreement entered into by the parties in December 2003 pursuant to which the Company licensed certain patents and patent applications relating to a process for the specific replacement of a copy of a gene in the receiver genome by homologous recombination. Pursuant to the License Agreement, the Company will make an up-front payment to Cellectis in the amount of $12,450,000.

In addition, the Company will pay Cellectis a low single-digit royalty based on revenue received by the Company from any future licenses or sales of the Company’s VelociGene® or VelocImmune® products and services. No royalties are payable with respect to the Company’s VelocImmune license agreements with AstraZeneca UK Limited and Astellas Pharma Inc. or the Company’s November 2007 collaboration agreement with sanofi-aventis. Moreover, no royalties are payable on any revenue from commercial sales of antibodies from the Company’s VelocImmune technology.

Regeneron Pharmaceuticals and Cellectis entered into a Subscription Agreement pursuant to which the Company will acquire 368,301 ordinary shares of Cellectis, par value EUR 0.05 per share, at a price of EUR 8.63 per share, for a total of EUR 3,178,437.63. The subscription is contingent upon the prior approval of the board of directors of Cellectis and by the shareholders of Cellectis at an extraordinary general meeting to be held no later than October 30, 2008.